Background: The duration of protection after hepatitis B ... antibody titers, 61% (33 of 54) and 67% (8 of 12), respectively, responded to a booster dose. In children of HBsAg-positive mothers ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...

Spontaneous loss of hepatitis B e antigen (HBeAg ... optimal drug regimen and timing of therapy for a patient with HBeAg-positive hepatitis. Accreditation: Tufts University School of Medicine ...

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

Updated Hep B Vaccine More Effective for People With HIV Dec. 10, 2024 — A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody ...

The hepatitis A virus (HAV) is one of the three main viruses that cause hepatitis, alongside the hepatitis B ... antibody test: This detects an antibody called immunoglobulin G (IgG) that persists in ...

antinuclear antibody titre ≥1:320, evidence of hepatitis B, hepatitis C or HIV infection, known sensitivity to methotrexate (MTX), sulphasalazine or hydroxychloroquine and systemic disease likely to ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...